-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3

Benzinga·09/16/2026 12:50:22
Listen to the news
Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.